A Vancouver-based pharmaceutical company will run the first take home psilocybin clinical trial in North America.

Health Canada has approved phase two of the trial by Apex Labs, which will evaluate the safety and efficacy of its low dose, multi-dose product APEX-52 in treating depression in veterans with post-traumatic stress disorder.

Learn More

Share this post